A method for developing in-silico protein homologs by McClatchy, Susan
New Jersey Institute of Technology
Digital Commons @ NJIT
Theses Theses and Dissertations
Fall 2002
A method for developing in-silico protein
homologs
Susan McClatchy
New Jersey Institute of Technology
Follow this and additional works at: https://digitalcommons.njit.edu/theses
Part of the Biostatistics Commons, and the Computer Sciences Commons
This Thesis is brought to you for free and open access by the Theses and Dissertations at Digital Commons @ NJIT. It has been accepted for inclusion
in Theses by an authorized administrator of Digital Commons @ NJIT. For more information, please contact digitalcommons@njit.edu.
Recommended Citation
McClatchy, Susan, "A method for developing in-silico protein homologs" (2002). Theses. 599.
https://digitalcommons.njit.edu/theses/599
 
Copyright Warning & Restrictions 
 
 
The copyright law of the United States (Title 17, United 
States Code) governs the making of photocopies or other 
reproductions of copyrighted material. 
 
Under certain conditions specified in the law, libraries and 
archives are authorized to furnish a photocopy or other 
reproduction. One of these specified conditions is that the 
photocopy or reproduction is not to be “used for any 
purpose other than private study, scholarship, or research.” 
If a, user makes a request for, or later uses, a photocopy or 
reproduction for purposes in excess of “fair use” that user 
may be liable for copyright infringement, 
 
This institution reserves the right to refuse to accept a 
copying order if, in its judgment, fulfillment of the order 
would involve violation of copyright law. 
 
Please Note:  The author retains the copyright while the 
New Jersey Institute of Technology reserves the right to 
distribute this thesis or dissertation 
 
 
Printing note: If you do not wish to print this page, then select  
“Pages from: first page # to: last page #”  on the print dialog screen 
 
The Van Houten library has removed some of
the personal information and all signatures from
the approval page and biographical sketches of
theses and dissertations in order to protect the
identity of NJIT graduates and faculty.
ABSTRACT
A METHOD FOR DEVELOPING
IN-SILICO PROTEIN HOMOLOGS
by
Susan McClatchy
Computational methods for identifying and screening the most promising drug
receptor candidates in the human genome are of great interest to drug discovery
researchers. Successful methods will accurately identify and narrow the field of
potential drug receptor candidates. This study details one such method.
The method described here begins with the assumption that novel drug
receptors have high sequence similarity to established drug receptors. The
similarity search program FASTA3 aligns translated sequences of the human
genome to known drug receptor sequences and ranks these alignments by
measuring their statistical significance. Query results returned by FASTA3 are
assembled into "in-silico proteins" or artificially generated homologs of known
drug receptors. A second similarity search program, BLASTP, aligns in-silico
proteins with a protein database, and also ranks alignments based on statistical
significance. A potentially valuable in-silico protein identifies its generating drug
receptor as the top-ranking result returned from the BLASTP search, and may
represent a new family member of a particular group of drug receptors.
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CHAPTER 1
INTRODUCTION
1.1 Objective
The completion of a draft sequence of the human genome in June of 2000
[International Human Genome Sequencing Consortium, 2001] amplified efforts
aimed at detection of genes serving as receptors for drugs. These efforts have
produced a multitude of promising new candidate drug receptors that must be
filtered thoroughly to find those best suited for new drug development.
Ultimately, those genes whose products make the best leads for drug
development must undergo rigorous experimental screening and analysis. Prior
to experimentation, computational methods may be employed to screen and
identify those genes most likely to serve as leads. This thesis details one
computational method for identifying and screening novel drug receptor genes.
The project described here aims to define and implement a procedure for
finding new members of any protein class, although it will focus on drug
receptors. This procedure creates in-silico proteins, or artificial homologs, from
query results obtained by searching a translation of the human genome with
known drug receptor sequences, using the similarity search program FASTA3.
An in-silico protein is verified if the BLASTP similarity search program finds that
it has highest similarity to the known drug receptor from which it was derived.
1
2Potential new members of a particular family of drug receptors may be found
among these verified in-silico proteins.
1.2 Background Information
A concise definition of a drug receptor begins with the drug receptor model
[Hardman, et. al., 20021 According to this model, a drug binds to a specific
receptor to form a drug-receptor complex, leading to some alteration of
physiological function. A drug with therapeutic value causes some desired
alteration of function, while undesired changes remain at an acceptable
minimum. In pharmaceutical parlance the phrase "drug target" is commonly
used in place of the phrase "drug receptor". The two phrases will be used
interchangeably from here on.
Most of the targets of marketed drugs are proteins whose role in biological
pathways may or may not be known. A focused search for new genomic drug
targets may include a hunt for relatives of genes involved in disease pathways,
or relatives of genes whose products are known to bind drugs therapeutically.
Computational searches for new drug targets frequently rely on methods for
identifying relatives by gene or protein sequence homology or protein structural
similarity.
These computational searches lie at the beginning of a continuum that
includes target screening, identification and validation [Branca, 2001 and
3Swindells & Overington, 2002]. Methods such as gene sequence and gene or
protein expression data mining provide minimal confidence, while experimental
methods, such as in vivo functional studies of genes inserted the mouse genome
(knockout mice), provide maximal confidence in the validation of a target.
Computational methods offer correlation between a supposed target and its role
in disease or therapy, while experimental methods imply direct causation
[Federsel, 2001]. The value of computational methods lie in their capacity to
screen large numbers of genes at once, eliminating many as poor candidates and
decreasing the labor required further downstream, where targets must be
validated in laboratory studies.
Correlative methods include use of gene expression microarrays to
identify genes with differential messenger RNA (mRNA) expression in various
states. A simple example of expression analysis would note differences in gene
expression between diseased and healthy tissue, or between treated and
untreated tissues. Serial Analysis of Gene Expression (SAGE) identifies genes
and quantifies gene expression by joining several short segments, or tags, of
mRNA from different genes. The joined tags are sequenced, identified, and
counted to create an expression profile for genes known and unknown.
Mining of expressed sequence tag (EST) databases may be used to identify
novel genes. Expressed sequence tags are partial sequences of complementary
DNA produced from reverse transcription of messenger RNA, and represent
genes expressed in a particular tissue under certain conditions. Expressed
4sequence tags may also be used to detect single nucleotide polymorphisms
(SNPs) in disease genes. Single nucleotide polymorphism association studies
compare disease and control populations, and compare allele frequency or
genetic variation between two groups.
Proteomics methods involve proteins rather than genes, and include
techniques for structural homology and mining of protein expression data. Using
the assumption that sequence similarity denotes structural similarity, homology
models may be generated for an unknown protein with high sequence similarity
to a well-characterized protein. For low sequence similarity, threading methods
are used. These structure-based methods may be useful in identifying likely
binding sites for drugs.
Protein expression data report on differential expression of a gene's final
product rather than the intermediary mRNA. Differential protein expression, like
differential gene expression, may be used to evaluate tissues in a disease state
versus a normal state. However, difficulties in purifying proteins hamper this
more direct means of measuring expression levels.
Most searches for new drug targets utilize sequence similarity search
programs. Resources such as HMMER and Pfam employ profile hidden Markov
models (HMMs) of protein domains or conserved regions to find new protein
family members [Bateman, et. al., 2002]. Hidden Markov models, originally
applied to speech recognition, define the probability of a given sequence of states
5and symbols [Durbin, et al., 2001]. An HMM may describe, for example, the
probability that a given sequence of amino acids (symbols) forms either an alpha
helix or a beta pleated sheet (state). Profile HMMs best describe multiple
alignments of protein family members, and are better suited to finding new
members fitting a particular profile than are pairwise alignment tools such as
FASTA and BLAST.
Programs like BLAST and FASTA measure the statistical significance of a
local alignment between two sequences, rather than simply measuring percent
sequence identity. Evaluating an alignment by percent sequence identity alone
fails to recognize that short sequences may have very high sequence identity
simply by chance [Wood & Pearson, 1999]. These latter two programs were used
extensively to create in-silico proteins, and are described in further detail.
1.2.1 FASTA
In aligning sequences, FASTA creates a lookup table to rapidly locate identities
between two sequences [Lipman & Pearson, 1985]. The name and position of
each residue is maintained in the table, and offset values calculated for each pair
of identical residues. An example follows.
6Example 1.1 Position offsets for identical residues are calculated and stored in a
lookup table.
The lookup table indicates that for Sequence 1, A is found at Positions 1, 3
and 6, R at Position 4 and G at 5. Positions of residues in Sequence 2 are
compared to those in Sequence 1. So, the R at Positions 1 and 3 of Sequence 2 is
found at Position 4 of Sequence 1, A at Position 5 is found at Positions 1, 3 and 6
of Sequence 1, and G at Position 4 found at Position 5 in Sequence 1. For each
pair of identities, an offset value is calculated. For example, the R at Position 1 in
Sequence 2 matches the R at Position 4, with an offset of 4 - 1 = 3. The R at
Position 3 also matches with the R at Position 4 of Sequence 1, with an offset of 1.
The G at Position 4 has an offset of 1 with respect to the G in Sequence 1. The A
at Position 5 has offset values of -4, -2 and 1. An offset of 1 would have 3 identical
residue matches (R, G, and A in both sequences) while other offset values would
have one or no matches.
This example describes a lookup table for length ktup = 1. Another typical
value for the FASTA parameter ktup is 2. In this case, FASTA would create a
lookup table for pairs of residues, such as R G or G A in the two sequences
above.
7The algorithm proceeds with a diagonal method, placing each sequence
on either the horizontal or vertical axis of a dot-matrix plot. Diagonal lines in the
plot indicate identities having the same offset. The score for each diagonal is
increased for each identity and decreased for each mismatch. The highest scoring
diagonals represent areas of greatest local similarity, and are selected for re-
scoring using an amino acid substitution matrix such as PAM-250. The use of a
substitution matrix takes into the account the greater likelihood of an amino acid
substitution, rather than an insertion or deletion. Matrices like PAM-250 also
account for greater likelihood of conserved substitution, where one amino acid
replaces another of similar character. The matrix would give a higher score to the
replacement of one hydrophobic amino acid with another, for example, and a
lower score to replacement of a hydrophobic with a hydrophilic residue.
Substitution matrices are defined further in the discussion of the BLAST
program.
For each of the highest scoring diagonals, a subregion, or initial region, of
maximal similarity is located. If compatible, initial segments may be joined to
form a single optimal alignment.
Alignment scores in FASTA are scaled to correct for the length
dependence of similarity scoring. Statistical significance of these scores is
calculated from the distribution of alignment scores of unrelated sequences
[Pearson, 1998]. After parameter estimation for location and scale, similarity
Sscores for FASTA follow an extreme-value distribution. The statistical
significance of length-corrected alignment scores may be calculated from this
distribution. The expectation value (e-value) in FASTA provides a measure of
statistical significance of alignment scores.
1.2.2 Basic Local Alignment Search Tool (BLAST)
The BLAST family of programs performs sequence similarity searches by finding
similar segments between query and subject, and computing the statistical
significance of the alignment of these segments. The basic unit of BLAST output
is the High Scoring Pair (HSP), or "hit". The following discussion of algorithms
and statistics refers to the BLASTP program, which compares protein queries
against protein databases [Altschul, et a1.,1997].
The BLAST program begins by creating a list of equal-length high-scoring
words between two sequences that meet parameters for score threshold T and
word length W. Like FASTA, scores are calculated from substitution matrices,
though they are not corrected for length. The BLAST program extends these
words and attempts to find segments of maximal cumulative score, or HSPs.
For each HSP, BLAST reports a raw score S calculated from a substitution
matrix, and a score normalized by statistical parameters and K that describe the
"scale" and "location" of the distribution of alignment scores [Pearson, 19981
These two parameters are calculated from a random model providing
9background frequency Pi for each amino acid position in a protein, and a score sii
for alignment of two amino acids using a given substitution matrix. Equation 1.1
defines the expected score for two random amino acids.
Normalization of raw scores with parameters As and K allows score
comparison of alignments using different substitution matrices. Normalized
scores S' are reported in bits, and are calculated from the equation:
The program reports an expectation value, or e-value, which describes the
probability that the bit score S' occurs by random chance. An e-value of 0.01, for
example, says that you can expect to see an equal or higher score by chance in 1
out of 100 alignments. Equation 1.3 defines calculation of the e-value.
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The values m and n represent lengths of two protein sequences, and their
product the size of the effective search space, or space of all possible solutions.
When applied to a protein database, the value n represents the length, or number
of residues, in the database. The BLAST program reports those HSPs with e-
values less than the default cutoff of 10.
1.2.3 E-value Thresholds
Determination of a threshold or cutoff for e-values is subjective, depending on
the investigator's concern for either a false-positive (Type I) or false-negative
(Type II) error. Higher e-value thresholds invite more of the former, and lower
thresholds more of the latter type of error. Since e-value increases linearly with
database size (see Equation 1.3), the choice of smaller databases offers
proportionally smaller e-values and greater sensitivity in the search for
homology. Typical e-value cutoffs for small-scale homology searches may be
from 0.001 to 0.01, while for large-scale searches involving thousands of
sequences, thresholds may typically be set from 10 -20 to 10-6.
1.2.4 Reference Sequence Project (Refseq)
The Refseq project at the National Center for Biotechnology Information (NCBI)
contains a non-redundant set of reference sequences for genomic contigs
(overlapping collections of DNA sequences or clones), mRNA and proteins for
humans and other organisms including mouse and rat. Curated Refseq records
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contain information compiled from multiple sources, so that each record
provides current knowledge of known genes. The value of Refseq lies in the
curation and review of each record and the non-redundancy of the database. For
the implementation of this project, all known drug target protein sequences were
retrieved from the Refuse protein database, RefseqP.
1.2.5 Draft Sequence of the Human Genome
Shortly after completion of sequencing and assembly, a draft version of the
human genome was made publicly available. The draft is the product of 20
international sequencing centers, and at present is in an 85% finished, highly
accurate state. Sequencing work continues, and periodic updates or "freezes"
occur frequently. The final version of the human genome sequence is projected
for completion in April of 2003. The genome may be searched at public websites
including GenBank at the National Center for Biotechnology Information and the
University of California Santa Cruz Genome Bioinformatics sites.
The draft genome produced by the International Human Genome
Sequencing Consortium employed a strategy known as hierarchical shotgun
sequencing. In this method, genomic DNA is fragmented and inserted into a
cloning vector, commonly a bacterial artificial chromosome (BAC). The set of
cloned DNA fragments represents a genomic library, which are organized into a
physical map spanning the entire genome. Selected BAC clones are sequenced
with the random shotgun strategy, and clone sequences assembled into the full
12
genome sequence after filtering for cross-species contaminant data and merging
sequence data from overlapping clones [International Human Genome
Sequencing Consortium, 20011
Because the human genome is composed of at least 50% repeated
sequence, assembly requires screening for known repetitive sequences. In the
genome assembly described here, the RepeatMasker program from Washington
University was employed to screen for annotated repetitive sequences and low
complexity regions. The sequence output of this program shows a series of N's in
place of repetitive sequences and low complexity regions.
Translation of DNA sequence data into protein sequence data may be
performed automatically in the following way. Each transcribed three-nucleotide
DNA codon is translated into a single amino acid using a codon table. A sliding
window produces three different reading frames in both forward and reverse
directions by advancing the frame one nucleotide at a time. A six-frame
translation results from reading all three frames in each of two directions. To
differentiate protein coding from non-coding regions, the procedure finds start
codons, which start the process of translation, and stop codons, which terminate
translation. A six-frame translation provides DNA sequence translation between
two start codons, between a start and a stop codon, and between two stop
codons. Functional genes are characterized by the presence of a sequence of
nucleotides that are transcribed into at least one start codon and stop codon.
Transcription of a gene produces open reading frames (ORFs), frames consisting
13
of a series of codons without stop codons that may potentially be translated into
protein. Figure 1.1 gives a graphical representation of a six-frame translation.
Searching a translation of the genome, rather than genomic DNA itself, is
preferable for a number of reasons. Sequence similarity measured by percent
sequence identity alone is inferior to similarity determined from substitution
matrices such as the PAM-250 matrix, which recognizes conservative
substitutions of one amino acid for another with like properties [Wood &
Pearson, 1999]. Amino acid sequence searches offer much greater sensitivity than
DNA searches as a result of the use of substitution matrices. In addition,
searching a translation of the entire genome sequence allows detection of novel
genes. A direct search of a protein database will find homologs of already known
genes, not as yet unidentified ones.
CHAPTER 2
DEVELOPING IN-SILICO PROTEINS
2.1 Problem Statement
With a draft of the human genome now completed, attention has turned to
analyzing genes and their protein products, particularly for disease relevance
and drug discovery. While newer tools like gene expression arrays and EST
databases have identified many gene products as potential targets, they have
also inundated pharmaceutical laboratories with a backlog of targets to screen
through much more laborious and costly procedures [Federsel, 2001]. A new
challenge has arisen in "prioritizing the proteome" [Swindells & Overington,
2002] and in identifying the most likely new drug targets. Computational means
can identify and screen potential targets and produce the best candidates for the
laboratory, thereby streamlining drug discovery and eliminating much of the
labor involved in target validation.
The procedure implemented here identifies genes with target potential,
using targets of marketed drugs to start the search. It is based on the assumption
that novel targets will have high sequence similarity to established drug
receptors.
14
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2.2 Procedure for Creating In-silico Proteins - An Overview
Creation of in-silico drug target homologs entails these steps:
1. Identify all known targets of marketed drugs.
2. Retrieve accession numbers and sequences of all known targets from a
protein database.
3. Query the translated human genome with all target protein sequences.
4. Assemble hits to the translation into in-silico proteins.
5. Check in-silico protein similarity to the original drug target sequence by
querying the protein database in step 2 with in-silico sequences.
This procedure for creating in-silico proteins is based on one developed by
Jeff Yuan at Merck Research Labs. Jeff devised a means for generating in-silico
gene homologs, or "working genes." Alex Elbrecht recognized the utility of this
procedure in generating in-silico protein homologs for drug targets or other
protein classes, and supervised the work described in the following pages. Bruce
Bush, also of Merck Research Labs, provided the genome translation and a Perl
script used in steps 3 and 4 above to assemble in-silico proteins from FASTA3
hits.
CHAPTER 3
IMPLEMENTATION
3.1 Identifying Known Drug Targets
In the absence of a comprehensive and commercially available list of known
drug targets, a list was compiled from Goodman & Gilman's The Pharmacological
Basis of Therapeutics, the Investigational Drugs Database, and DrugBank (see
refs.). Target names extracted from these three resources were used as queries to
two protein databases, Swissprot and RefseqP. The compiled list of drug targets
is shown in Table A.1.
3.2 Protein Sequence Retrieval
Both Swissprot and RefseqP provide protein annotation, sequence data and links
to literature. In many cases, simply evaluating the list of protein names returned
for a text query was sufficient to determine which retrieved proteins fit the
description for a given drug target. In other cases, a review of the annotation
from both databases thinned the number of proteins retrieved. For example,
annotation mentioning a protein's role in disease or the fact that it
therapeutically bound a drug identified it as the desired receptor.
16
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In many cases, a selected protein had multiple transcript variants and
isoforms. When annotation did not designate a specific variant or isoform as a
target, all splice variants and isoforms were included.
The final list contained 377 RefseqP accession numbers representing
known human therapeutic drug target proteins. Amino acid sequences for each
of these 377 accession numbers were retrieved from the RefseqP database.
3.3 Searching the Translated Human Genome
Drug target sequences were queried against a six-frame translation of the April
2002 human genome assembly released by the UCSC Human Genome Project,
also known as Golden Path. The assembly was repeat-masked, or screened for
repetitive sequences or low complexity regions. Known repetitive sequences and
regions of high uncertainty are represented by strings of X's in the translation.
The FASTA3 program was employed to search the translation. When
compared to other similarity search programs including BLAST, FASTA3 is, in
general, more accurate [Pearson, 1998] and more sensitive to detection of
homologs [Jeff Yuan, manuscript in preparation].
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3.4 In-silico Protein Assembly
Hits to the translated genome, which represent open reading frames, were
assembled into in-silico proteins if FASTA3 had assigned an e-value less than 1.0.
This cut-off e-values was chosen through the experience of Jeff Yuan, who has
found relevant FASTA3 hits with e-value slightly less than 1.0. The ORFs were
sorted by chromosome, by index number and by orientation (forward or
reverse). Regions between ORFs are represented by four dashes (—). The
procedure assembled 55,465 in-silico proteins from the FASTA3 output. Sample
FASTA3 output and in-silico protein sequence are shown in Figure B.1.
3.5 Verifying In-silico Proteins
Once assembled, all in-silico proteins were searched against the RefseqP human
protein database using ungapped BLAST set to return only the topmost hit. Since
BLAST ranks hits by increasing e-value, the first hit in most cases will have the
highest similarity to the query sequence. Comparing the accession numbers of
the generating protein and the first hit is a simple and quick task. If the first
BLAST hit for an in-silico protein was its generating protein, the in-silico protein
was considered a verified target homolog. Later, a modification of this procedure
included reporting of several hits, since identical e-values may appear for
transcript variants producing identical proteins. This modification is described
further along with results.
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3.6 Parsing BLAST reports
Each in-silico protein returned a BLAST report, resulting in 55,465 individual
reports. In most of these reports, the generating drug target was not the top hit
for that in-silico protein. Since initially only the top hit is considered valid in this
procedure, most of these reports were overlooked in favor of those returning the
generating target as the top hit.
A BLAST report parser, written in the Pearl programming language, was
employed to scroll through each file and compare the RefseqP accession number
of an in-silico protein's generating target with that of the top hit. If the accession
numbers were identical, the parser extracted additional information from the file,
including the name of the hit, HSP lengths and e-values, and bit scores. The
parser code, which relies on the Bioperl module BPlite, is shown in Section C.1.
Sample parsed BLAST output is shown in Section C.2.
3.7 Results
The procedure described above produced 55,465 in-silico proteins representing
377 drug targets. Of these 55,465 in-silico proteins, 1,203 (2.17%) successfully
found their generating drug target as the topmost hit returned from BLAST.
Figure 3.1 compares the number of drug targets with the number verified
in-silico proteins. Of 377 targets, 54 failed to generate any in-silico proteins that in
turn found them as first BLAST hit, and 109 targets had exactly one in-silico
20
protein finding self. In most of these one-hit cases, the in-silico protein represents
the actual target itself. The remaining 214 targets had two or more in-silico
proteins that were more similar to them than to any other protein in the RefseqP
database.
A review of the 54 drug targets with no in-silico protein top hits to self
revealed that splice variants of many of these 54 appeared first in BLAST reports.
In some cases the longest of a set of variants returned the lowest e-value. Since
raw alignment scoring is cumulative (Equation 1.1), longer splice variants may
return higher scores and lower e-values simply as a function of their length.
Figure B.2 shows one example. In other cases, a set of splice variants from a
single gene coded for identical proteins. While the target generating an in-silico
21
protein may not have appeared first, it may have appeared further down the list
and may have had the same é-value as the first hit listed. An example is shown in
Figure B.3.
A review of the 109 drug targets with one in-silico protein top hit to self
revealed that some of these verified in-silico proteins were located on a different
chromosome than the drug target that generated them. In most of these cases, as
in the case above, BLAST returned the longest of a set of splice variants, or one of
several identical proteins as top hit.
In-silico proteins for drug targets having no top hits to self, as well as those
having in-silico proteins located on different chromosomes than self, were
BLASTed again and the top six or twelve hits reported. Listing of the top twelve
hits was required only for a set of identical fibroblast growth factor receptors
(FGFR2), which have a dozen identical proteins from as many splice variants.
Others had a maximum of six splice variants and required reporting of only the
top six hits.
Figure 3.2 Revised BLAST report summary for in-silico proteins. These BLAST
reports returned either 6 or 12 hits in order to capture equal e-values for multiple
splice variants.
After testing the top six or twelve BLAST hits for lowest e-value, nine
drug targets having no in-silico protein top hits to self remain. Peroxisome
proliferative activated receptor (PPAR) gamma, isoform 1 (Refseq accession
number NP 61972b) demonstrates the BLAST program's assignment of lowest e-
value to longest splice variants. In three of the BLAST reports for PPAR gamma,
other variants of PPAR including alpha and delta received the lowest e-value.
PPAR gamma received higher e-value scores than these variants in spite of the
fact that its sequence had fashioned the in-silico proteins. The other eight drug
targets returned similar results or failed to generate successful in-silico proteins
for reasons that can only be revealed by a thorough analysis of their sequence
and relationships to other proteins.
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The number of targets having one in-silico protein finding self increased
from 109 to 130 as a result of examination of several hits instead of only the first.
Most of these in-silico proteins represent the sequence of the actual target itself.
The remaining 238 drug targets had two or more in-silico homologs that
identified them as the hit with lowest e-value, some of which may represent
novel targets.
CHAPTER 4
CONCLUSIONS
This procedure for generating in-silico protein homologs from genomic sequence
data is shown to be effective given the following summary of results. Greater
than two percent of in-silico proteins generated have highest similarity to their
generating target as measured by BLAST e-value. A very simple measure of the
success of this procedure is the existence of at least one verified in-silico protein
homolog per drug target. If successful, the procedure should at a minimum
produce one in-silico homolog representing the sequence of the generating drug
target itself. Only 9 of 377 drug targets were unable to generate verified in-silico
homologs.
Another measure of this procedure's effectiveness is the existence of
multiple in-silico homologs representing the same drug target. As shown by
Figure 3.2, 238 drug targets have more than one verified in-silico protein. Some of
these in-silico proteins may represent novel genomic targets that have as yet not
been found or characterized. Thorough analysis and review of these in-silico
homologs is required in order to locate potential new targets. Once located, other
procedures such as microarray expression or EST analysis may be employed for
further screening.
24
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Of the 130 drug targets having only one verified in-silico homolog,
approximately 10% generated in-silico homologs located on chromosomes other
than their own, indicating an error rate of —10% in the procedure. Longer splice
variants accumulated higher BLAST raw scores and lower e-values than their
shorter counterparts, effectively drawing in-silico proteins generated by shorter
variants nearer to themselves. For these cases, more rigorous algorithms than
those used by BLASTP, especially those that correct for query sequence length,
may be employed to refine alignments and to find the generating target at its
correct location within the genome.
The procedure as detailed requires input of a set of protein accession
numbers and some file manipulation. Aside from this, very little user
intervention is needed. No decision needs to be made by the user regarding e-
value cutoffs, nor any criteria established to determine the validity of a hit. An
automatic e-values cutoff of 1.0 for FASTA3 results during in-silico protein
assembly is liberal enough to include homologous sequences, yet exclusive
enough to produce in-silico proteins of adequate specificity. No e-value cutoff is
required for BLAST results, since only the top-ranking hits are evaluated. The
output of the procedure, a set of in-silico protein homologs, is a valuable
collection that potentially contains new genomic drug targets. Once complete,
the set requires analysis and further study in order to determine whether novel
targets have been discovered.
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The procedure itself may be applied to any group or subgroup of proteins.
In upcoming work this procedure will be utilized to create in-silico homologs of
disease-related proteins, which will also be studied for identification of novel
drug targets.
APPENDIX A
KNOWN HUMAN DRUG TARGET PROTEINS
Table A.1 shows the compiled list of 377 human drug target proteins. This list
does not include drug metabolizing proteins.
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APPENDIX B
FASTA3 AND BLASTP OUTPUT
Appendix B gives examples of BLASTP and FASTA3 program outputs and in-
silico protein sequences.
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APPENDIX C
BLAST PARSER CODE AND SAMPLE OUTPUT
Appendix C shows Pearl code for the BLAST parser employed to retrieve data
from BLASTP output files. Sample BLAST parser output follows.
Section C.1 Pearl code for BLAST parser.
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